Method and composition for inhibition of angiogenesis using antagonists based on MMP-9 and β1 integrins
Antagonists for modifying protein-protein interactions involving certain amino acid sequences within MMP-9 and/or β1 integrins are described. Such antagonists inhibit angiogenesis, tumor growth and disease states. Example antagonists are polypeptide and non-polypeptide molecules, including the novel antibody Mab FM155 and the novel synthetic peptide FRIP-1. Methods for inhibiting angiogenesis and disease states by administering such antagonists are disclosed. Methods for identifying antagonists that modify protein-protein interactions involving certain amino acid sequences within MMP-9 and/or β1 integrins are also described.
1. An isolated antagonist that inhibits angiogenesis, tumor growth, or metastasis by modifying protein-protein interactions between MMP-9 and a β1-containing integrin, wherein the isolated antagonist comprises an antibody reagent which specifically hinds to a polypeptide comprising SEQ ID NO: 1.
2. The isolated antagonist of claim 1 wherein the β1-containing integrin is α5β1 integrin.
3. The isolated antagonist of claim 1 wherein the protein-protein interactions cause co-localization of matrix metalloproteinase 9 (MMP-9) and a β1-containing integrin on the cell surface of a blood vessel.
4. The isolated antagonist of claim 1 wherein said isolated antagonist is a monoclonal antibody.
5. The isolated antagonist of claim 1 wherein the isolated antagonist is a polyclonal antibody.
6. The isolated antagonist of claim 1 wherein the isolated antagonist is a humanized or chemically modified monoclonal antibody.
7. The isolated antagonist of claim 1 wherein the isolated antagonist is a fragment of a monoclonal antibody.
8. The isolated antagonist of claim 1 wherein the isolated antagonist is conjugated to cytotoxic or cytostatic agents.
9. A method of inhibiting angiogenesis in a tissue comprising administering the isolated antagonist of claim 1 .
10. The method of claim 9 wherein said isolated antagonist is administered intravenously, transdermally, intrasynovially, intramuscularly, intratumorally, intraocularly, intranasally, intrathecally, topically or orally.
11. The method of claim 9 wherein said isolated antagonist is administered in conjunction with chemotherapy.
12. The method of claim 9 wherein said isolated antagonist is administered in conjunction with radiation.
13. The method of claim 9 wherein the tissue is inflamed and angiogenesis is occurring.
14. The method of claim 13 wherein the tissue is present in a mammal.
15. The method of claim 14 wherein the tissue is arthritic, ocular, retinal or a hemangioma.
16. A method of inhibiting tumor growth or metastasis in a tissue comprising administering the isolated antagonist of claim 1 .
17. The method of claim 16 wherein said isolated antagonist is administered intravenously, transdermally, intrasynovially, intramuscularly, intratumorally, intraocularly, intranasally, topically or orally.
18. The method of claim 16 wherein said isolated antagonist is administered in conjunction with chemotherapy.
19. The method of claim 16 wherein said isolated antagonist is administered in conjunction with radiation.
20. The method of claim 16 wherein the tumor or metastasis is a melanoma, carcinoma, sarcoma, fibrosarcoma, glioma or astrocytoma.
21. A method of inhibiting psoriasis, macular degeneration, or restenosis in a tissue by administering the isolated antagonist of claim 1 .
22. The method of claim 21 wherein said isolated antagonist is administered intravenously, transdermally, intrasynovially, intramuscularly, intratumorally, intraocularly, intranasally, intrathecally, topically or orally.
23. The method of claim 21 wherein administering the isolated antagonist is in conjunction with chemotherapy.
24. The method of claim 21 wherein administering the isolated antagonist is in conjunction with radiation.